MTOR and neoplasm: To evaluate alterations in kinase levels following treatment with dasatinib, we measured expression of p-Lyn, p-PI3K, p-Akt, and p-mTOR in tumor tissues of the Jeko1/BTZ xenografted model (Figure 5F).